Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Scott Karlan"'
Autor:
Oukseub Lee, Latifa A. Bazzi, Yanfei Xu, Erik Pearson, Minhua Wang, Omid Hosseini, Azza M. Akasha, Jennifer Nam Choi, Scott Karlan, Melissa Pilewskie, Masha Kocherginsky, Kelly Benante, Thomas Helland, Gunnar Mellgren, Eileen Dimond, Marjorie Perloff, Brandy M. Heckman-Stoddard, Seema A. Khan
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 171, Iss , Pp 116105- (2024)
Breast cancer prevention only requires local exposure of the breast to active drug. However, oral preventive agents entail systemic exposure, causing adverse effects that limit acceptance by high-risk women. Drug-delivery through the breast skin is a
Externí odkaz:
https://doaj.org/article/866b000bd0524b18baec1ef3a47518c6
Autor:
Lei Zhang, Hua Xiao, Scott Karlan, Hui Zhou, Jenny Gross, David Elashoff, David Akin, Xinmin Yan, David Chia, Beth Karlan, David T Wong
Publikováno v:
PLoS ONE, Vol 5, Iss 12, p e15573 (2010)
A sensitive assay to identify biomarkers using non-invasively collected clinical specimens is ideal for breast cancer detection. While there are other studies showing disease biomarkers in saliva for breast cancer, our study tests the hypothesis that
Externí odkaz:
https://doaj.org/article/b85cc7ee85a944ff9d8d7b34122400b9
Autor:
Michèl Schummer, Ann Green, J David Beatty, Beth Y Karlan, Scott Karlan, Jenny Gross, Sean Thornton, Martin McIntosh, Nicole Urban
Publikováno v:
PLoS ONE, Vol 5, Iss 2, p e9122 (2010)
This study was initiated to identify biomarkers with potential value for the early detection of poor-outcome breast cancer. Two sets of well-characterized tissues were utilized: one from breast cancer patients with favorable vs. poor outcome and the
Externí odkaz:
https://doaj.org/article/d35c6e4e35b94f56bd0f3b11c6bf6fe1
Autor:
Michèl Schummer, Ann Green, J. David Beatty, Beth Y. Karlan, Scott Karlan, Jenny Gross, Sean Thornton, Martin McIntosh, Nicole Urban
Publikováno v:
PLoS ONE, Vol 5, Iss 4 (2010)
Externí odkaz:
https://doaj.org/article/589742922fbc4bd8a6c508283eef3b95
Autor:
Catherine Dang, Alice Y. Ho, Stephen L. Shiao, Reva Basho, Farin Amersi, Dorothy J. Park, Monica M. Mita, Armando E. Giuliano, Michele Burnison, Cynthia Martin, Alice Chung, Cathie Chung, Brittany Arnold, Negin Habibi Khameneh, Simon R.V. Knott, Nimmi S. Kapoor, Heather L. McArthur, Philomena McAndrew, Scott Karlan, Christina DiLauro Abaya
Publikováno v:
Cancer Research. 81:PS12-09
Background: Pembrolizumab (pembro)-mediated checkpoint blockade has shown only modest efficacy in triple negative breast cancer (TNBC). Pathologic complete response (pCR) rates in TNBC are 34-55% with neoadjuvant chemotherapy and 26% with neoadjuvant
Autor:
Marjorie Perloff, Kelly A. Benante, Shivangi Yadav, Nora M. Hansen, Eileen Dimond, Yanfei Xu, Brandy M. Heckman-Stoddard, Miguel Muzzio, Masha Kocherginsky, Omid Hosseini, Kevin P. Bethke, Mary Beth Tull, Luis Z. Blanco, Irene Helenowski, Seema A. Khan, Oukseub Lee, Melissa A. Troester, Melissa Pilewskie, Scott Karlan
Publikováno v:
Clin Pharmacol Ther
Oral breast cancer prevention medications entail systemic exposure, limiting acceptance by high-risk women. Delivery through the breast skin, although an attractive alternative, requires demonstration of drug distribution throughout the breast. We co
Autor:
Heather McArthur, Stephen Shiao, Scott Karlan, Farin Amersi, Brittany Arnold, Reva Basho, Michele Burnison, Alice Chung, Cathie Chung, Catherine Dang, Armando Giuliano, Negin Habibi Khameneh, Simon Knott, Cynthia Martin, Philomena McAndrew, Monica Mita, Dorothy Park, Christina Abaya, Alice Ho
Publikováno v:
Cancer Research. 80:P3-09
Background: Pembrolizumab (pembro)-mediated checkpoint blockade has shown modest efficacy in triple negative breast cancer (TNBC). Pathologic complete response (pCR) rates in TNBC are 34-55% with neoadjuvant chemotherapy (Cortazar Lancet 2014, Sharma
Autor:
Heather L McArthur, Stephen Shiao, Scott Karlan, Reva Basho, Farin Amersi, Michele Burnison, Amin Mirhadi, Alice Chung, Cathie T Chung, Catherine Dang, Heather Richardson, Armando E Giuliano, Nimmi Kapoor, Brigid Larkin, Hector Godinez, Samantha A Dunn, Negin Habibi Khameneh, Simon Knott, Philomena McAndrew, Monica Mita, Dorothy J Park, Christina Abaya, Jonathan H Chen, Amy Ly, Veerle Bossuyt, Alice Ho
Publikováno v:
Cancer Research. 82:PD10-01
Background: Anti-PD(L)1 in addition to neoadjuvant chemotherapy (NAC) can achieve pathologic complete response (pCR) rates of up to 65% in patients with early stage triple negative breast cancer (TNBC). However, patients with non-pCR can have dismal
Autor:
Heather McArthur, Jorge Leal, David Page, Christina DiLauro Abaya, Reva Basho, Lindsey Ristow, Hannah Coleman, Stephen Shiao, Simon Knott, Monica Mita, Mourad Tighiouart, Alice Chung, Farnaz Dadmanesh, Philomena McAndrew, Scott Karlan, Sunil Verma, Armando Giuliano
Publikováno v:
Cancer Research. 80:OT2-04
Background: Immune checkpoint inhibition (ICI) is synergistic with HER2-directed therapy in pre-clinical models. Clinically, pembrolizumab (K)-mediated ICI plus HER2-directed therapy with trastuzumab (H) was safe and demonstrated modest activity in H
Autor:
Oukseub Lee, Melissa Pilewskie, Scott Karlan, MB Tull, Marjorie Perloff, Kevin P. Bethke, Brandy M. Heckman-Stoddard, Irene Helenowski, KA Benante, Nora M. Hansen, Borko Jovanovic, Seema A. Khan, Miguel Muzzio, Y Xu, Eileen Dimond, Luis Z. Blanco, Swati Kulkarni
Publikováno v:
Cancer Research. 79:P6-21
Background: Low uptake and poor adherence to oral drugs for breast cancer prevention and ductal carcinoma in situ has led to an interest in local routes of delivery with the intent of decreasing systemic exposure and reducing toxicity. LTT has emerge